Skip to main content

Asuragen Launches miRNA Rx Spinout

NEW YORK (GenomeWeb News) – Asuragen today announced that it has spun out its microRNA-based therapeutics intellectual property into a new company called Mirna Therapeutics.
 
Specific details about the structure and focus of Mirna were not disclosed.
 
“The discovery of miRNAs represents a paradigm-changing event in biology and medicine of a magnitude that only occurs once every decade or two," Asuragen CEO and CSO Matt Winkler said in a statement. “They likely will become a major new class of drugs.”
 
As reported by GenomeWeb Daily News sister publication RNAi News in January, the new company is initially being funded with $3 million from Asuragen.
 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.